发明名称 Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway
摘要 The disclosure relates to dihydropyrazino[2,3-h]pyrazin-2(1H)-one derivative compounds of structural formula shown herein or a salt, tautomer or stereoisomer thereof, wherein: X is halogen, B(OR+)2 or Sn(R++)3; R2 is H, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl; R3 is H, or a substituted or unsubstituted C1-8 alkyl; each R+ is independently hydrogen or substituted or unsubstituted C1-3 alkyl, or each R+, together with the boron atom and the atoms to which they are attached, form a cyclic boronate; and R++ is a C1-4 alkyl. These compounds are suitable for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.
申请公布号 NZ619458(A) 申请公布日期 2015.07.31
申请号 NZ20090619458 申请日期 2009.10.27
申请人 SIGNAL PHARMACEUTICALS LLC 发明人 ELSNER JAN;HARRIS ROY L;LEE BRANDEN;MORTENSEN DEBORAH;PACKARD GARRICK;PAPA PATRICK;PERRIN-NINKOVIC SOPHIE;RIGGS JENNIFER;SANKAR SABITA;SAPIENZA JOHN;SHEVLIN GRAZIELLA;TEHRANI LIDA;XU WEIMING;ZHAO JINGJING;PARNES JASON;MADAKAMUTIL LOUI;FULTZ KIMBERLY;NARLA RAMA K
分类号 C07D487/04;A61K31/4985;A61P35/00 主分类号 C07D487/04
代理机构 代理人
主权项
地址
您可能感兴趣的专利